TITLE

Passé et futur de la LMC: allogreffe de CSH, omacetaxine et ponatinib

AUTHOR(S)
Nicolini, F.; Michallet, M.
PUB. DATE
October 2012
SOURCE
Oncologie;Oct2012, Vol. 14 Issue 10/11, p613
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Allogeneic hematopoietic stem cell transplantation has been and still the only curative treatment for chronic myeloid leukemia (CML), despite its complications and high mortality rates. It still keeps its place in the CML treatment arsenal even with the availability of first and second generations of tyrosine-kinase inhibitors. Patientswho fail to respond to the previously cited treatments combined or as single therapy will have to evaluate new promising treatments with either omacetaxine mepesuccinate or ponatinib. We present in this paper a review of different past and near future treatment options for CML.
ACCESSION #
83780073

 

Related Articles

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...

  • Targeted therapies for CML: practical considerations and comparisons. Blamble, Debbie; Michaud, Laura Boenhnke // Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p14 

    The article discusses other targeted therapies that have been approved for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), since the approval of imatinib. Among them are two new tyrosine kinase (TK) inhibitors, dasatinib and nilotinib. A comparison between dasatinib, imatinib...

  • Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. Harnicar, Stephen; Mathew, Sherry // Blood & Lymphatic Cancer: Targets & Therapy;Aug2014, Vol. 4, p61 

    Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML). By targeting the BCR-ABL fusion oncogene, the introduction of tyrosine-kinase inhibitors (TKIs) has dramatically improved the outcomes of this disease. Nilotinib is a...

  • Omacetaxine as an Anticancer Therapeutic: What is Old is New Again. Wetzler, Meir; Segal, David // Current Pharmaceutical Design;1/1/2011, Vol. 17 Issue 1, p59 

    No abstract available.

  • Imatinib en première ligne dans la LMC en 2012: un traitement « dépassé » ? Giraudier, S. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p579 

    The initial management of chronic myeloid leukemia (CML) in chronic phase is now based solely on treatment with tyrosine-kinase inhibitor (TKI). The development of second generation inhibitors and their use in first-line treatment raises the issue of choice of TKI in the first prescription....

  • Inhibiteurs de tyrosine-kinase de 2 génération et associations: perspectives. Coiteux, V. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p601 

    Second-generation tyrosine-kinase inhibitors enable an earlier and higher quality molecular response to be achieved than with imatinib in patients suffering from CML in chronic phase at diagnosis. This implies that in the future a larger number of patients will be candidates for the...

  • Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? RUMJANEK, Vivian M.; VIDAL, Raphael S.; MAIA, Raquel C. // Bioscience Reports;2013, Vol. 33 Issue 6, p875 

    The hallmark of CML (chronic myeloid leukaemia) is the BCR (breakpoint cluster region)-ABL fusion gene. CML evolves through three phases, based on both clinical and pathological features: a chronic phase, an accelerated phase and blast crisis. TKI (tyrosine kinase inhibitors) are the treatment...

  • Faktori koji utiču na postizanje i postojanost citogenetskog odgovora kod bolesnika sa hroničnom mijeloidnom leukemijom na terapiji imatinibom. Ćojbašić, Irena; Mačukanović-Golubović, Lana // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Nov2011, Vol. 68 Issue 11, p911 

    Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease. The aim of this study was evaluation and analysis of cytogenetic response in different...

  • Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Shah, Neil P. // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p49 

    The small molecule BCR-ABL-selective kinase inhibitor imatinib is the single most effective medical therapy for the treatment of chronic myeloid leukemia (CML). Although imatinib is highly effective initially and generally well tolerated, for patients who undergo relapse or disease progression...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics